Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Currency in USD	2025
Operating Income	98.35 Million
Income Before Tax	51.53 Million
Income Tax Expense	21.42 Million
Net Income	-1.63 Million
Eps	-0.01
Epsdiluted	-0.01
Weighted Average Shs Out	133.76 Million
Weighted Average Shs Out Dil	133.76 Million
Research And Development Expenses	607.16 Million
Selling General And Administrative Expenses	N/A
Depreciation And Amortization	22.20 Million
Interest Expense	89.36 Million
Interest Income	37.29 Million
Net Interest Income	-52.07 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	N/A
Ebitda	120.55 Million
Source	edgar
Ebit	140.89 Million

Arrowhead Pharmaceuticals, Inc. Annual Reports (10-K)